# US 2013/0252834 A1 · Diagnostic Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252834 A1
- Document ID: US20130252834A1
- Status: Published application
- Kind: A1
- Application number: 13/699,444
- Filed: 2011-05-23
- Published: 2013-09-26
- Earliest claimed: 2010-05-21
- Assignees: Universite De Geneve; Electrophoretics Limited
- Inventors: Loic Gerard Dayon; Jean-Charles Sanchez; Joan Montaner Villalonga
- Web page: https://patentgrep.com/patent/US20130252834A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12N 9/0065: {acting on hydrogen peroxide as acceptor (1.11)}
- C12N 9/1088: {Glutathione transferase (2.5.1.18)}
- C12Q 1/26: involving oxidoreductase
- C12Q 1/48: involving transferase
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A method of aiding the diagnosis of acute brain damage in a subject, the method comprising:
(i) assaying the concentration in a sample from the subject of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1; and
(ii) assaying the concentration in the sample from the subject of at least one further polypeptide selected from Panel A;
(iii) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for the polypeptides; and
(iv) determining that a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in the subject.

### Claim 44 (depends on 43)

A method according to claim 43, wherein step (ii) comprises:
assaying the concentration of at least one further polypeptide selected from Panel B, Panel C, Panel 1, Panel 1H, Panel 1C, Panel 1A, Panel 1B, Panel 2, Panel 2A, or Panel 2B.

### Claim 45 (depends on 43)

A method according to claim 43, wherein step (i) comprises:
(i) assaying the concentration of at least two oxidative stress polypeptides selected from the group consisting of: PRDX1, PRDX6 and GSTP1; or
(ii) assaying the concentration of each of the oxidative stress polypeptides PRDX1, PRDX6 and GSTP1.

### Claim 46 (depends on 43)

A method according to claim 43, wherein step (ii) comprises assaying the concentration of:
(i) at least two further polypeptides selected from Panel A; or
(ii) at least four further polypeptides selected from Panel A.

### Claim 47 (depends on 43)

A method according to claim 43, wherein the acute brain damage is stroke.

### Claim 48 (depends on 43)

A method according claim 43, wherein the sample is brain microdialysate fluid, cerebrospinal fluid, or blood.

### Claim 49 (depends on 43)

A method according claim 43, wherein step (i) comprises assaying the concentration of PRDX1 in a sample from the subject.

### Claim 50 (depends on 43)

A method according to claim 43, wherein the polypeptide is assayed by:
western blotting, bead suspension array or by planar array, isobaric protein tagging or by isotopic protein tagging, or mass spectrometer-based assay.

### Claim 51

An assay device, which comprises a solid substrate having a location containing a material, which recognizes, binds to or has affinity for a first and a second polypeptide or a fragment, variant, or mutant thereof, wherein the first polypeptide is selected from PRDX1, PRDX6 and GSTP1 and the second polypeptide is selected from Panel A.

### Claim 52

An assay device, which comprises a solid substrate having a location containing a material, which recognizes, binds to or has affinity for a polypeptide, or a fragment, variant, or mutant thereof, wherein the polypeptide is selected from Panel 2.

### Claim 53 (depends on 52)

An assay device according to claim 52, which has a unique addressable location for each antibody, thereby permitting an assay readout for each individual polypeptide or for any combination of polypeptides.

### Claim 54

A method of diagnosis or prognostic monitoring of acute brain damage in a subject, said method comprising:
(a) obtaining and extracting proteins from a relevant tissue sample from an individual;
(b) digesting said proteins to produce a population of peptides;
(c) determining the abundance of one or more of said peptides listed in Table 14 using Selected Reaction Monitoring of one or more of the transitions listed in Table 15;
(d) comparing the abundance of said one or more peptides with a pre-determined peptide abundance associated with a diagnosis of acute brain damage; and
(e) determining whether the subject has suffered acute brain damage and/or that the acute brain damage is worsening or improving based on the differences in abundance of said one or more peptides.

### Claim 55

A preparation comprising one or more synthetic peptides selected from the group listed in Table 14.

### Claim 56 (depends on 55)

A preparation according to claim 55, wherein said one or more synthetic peptides are selected from
(i) the following peptides from GSTP1:
TFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGR
MPPYTVVYFPVR
DDYVK
DQQEAALVDMVNDGVEDLR
FQDGDLTLYQSNTILR
ASCLYGQLPK
AFLASPEYVNLPINGNGK
MLLADQGQSWK
LSARPK
TLGLYGK
EEVVTVETWQEGSLK
ALPGQLKPFETLLSQNQGGK
YISLIYTNYEAGK;
(ii) the following peptides from PRDX1:
HGEVCPAGWKPGSDTIKPDVQK
QGGLGPMNIPLVSDPK
ADEGISFR
DISLSDYK
LVQAFQFTDK
IGHPAPNFK
LNCQVIGASVDSHFCHLAWVNTPK
YVVFFFYPLDFTFVCPTEIIAFSDR
MSSGNAK
TIAQDYGVLK
ATAVMPDGQFK;
(iii) from the following peptides from PRDX6:
GMPVTAR
MPGGLLLGDVAPNFEANTTVGR
DFTPVCTTELGR
VVFVFGPDK
LIALSIDSVEDHLAWSK
ELAILLGMLDPAEK
LSILYPATTGR
VATPVDWK
NFDEILR
LPFPIIDDR
VVISLQLTAEK
DINAYNCEEPTEK
LAPEFAK
DGDSVMVLPTIPEEEAK
FHDFLGDSWGILFSHPR;
(iv) from the following peptides from DDAH1:
ALPESLGQHALR
DENATLDGGDVLFTGR
DYAVSTVPVADGLHLK
GAEILADTFK
GEEVDVAR
QHQLYVGVLGSK
TPEEYPESAK;
(v) from the following peptides from CYTB:
HDELTYF
SQVVAGTNYFIK
VFQSLPHENKPLTLSNYQTNK
VHVGDEDFVHLR;
(vi) from the following peptides from ACBP:
MSQAEFEK
AAEEVR
QATVGDINTERPGMLDFTGK
TKPSDEEMLFIYGHYK
WDAWNELK
MWGDLWLLPPASANPGTGTEAEFEK
MPAFAEFEK;
(vii) from the following peptides from CSRP1:
GFGFGQGAGALVHSE
GLESTTLADK
GYGYGQGAGTLSTDK;
(viii) from the following peptides from MT3:
GGEAAEAEAEK
MDPETCPCPSGGSCTCADSCK
SCCSCCPAECEK;
and
(ix) from the following peptides from PEPB1:
GNDISSGTVLSDYVGSGPPK
LYEQLSGK
LYTLVLTDPDAPSR
NRPTSISWDGLDSGK
VLTPTQVK
YVWLVYEQDRPLK.

### Claim 57 (depends on 55)

A preparation according to claim 55, wherein each peptide contains one or more stable heavy isotopes selected from hydrogen, carbon, oxygen, nitrogen or sulphur.
